SCHEDULE: Tyndall Capital Trims Cyclerion Stake to 4.8%
Beneficial Ownership Statement
Tyndall Capital Partners, L.P. reports a 4.8% passive ownership stake in Cyclerion Therapeutics, Inc. as of June 30, 2025.
Summary
- Tyndall Capital Partners, L.P. filed an Amendment No. 3 to Schedule 13G, reporting its beneficial ownership in Cyclerion Therapeutics, Inc.
- As of June 30, 2025, Tyndall Capital Partners, L.P. beneficially owned 155,187 shares of Cyclerion Therapeutics, Inc. common stock.
- This ownership represents 4.8% of the Issuer's total 3,210,094 shares of common stock outstanding as of the same date, as reported in Cyclerion's Quarterly Report on Form 10-Q filed August 5, 2025.
- Tyndall Capital Partners, L.P. holds sole voting and sole dispositive power over all reported shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of passive beneficial ownership, providing factual data without indicating positive or negative operational performance or strategic shifts for the issuer.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a passive ownership stake by an investment firm in a biotechnology company. It does not provide information on broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, albeit passive, ownership stake by an institutional investor.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement (ownership snapshot). |
| 08/05/2025 | Date Cyclerion Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, which provided the shares outstanding count. |
| 08/14/2025 | Date the Schedule 13G was signed by Tyndall Capital Partners, L.P. |
Keywords
Cyclerion Therapeutics, Tyndall Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.